Ian Hoban Joins Pilatus Clinical Services

Food and Healthcare Press Releases Thursday October 5, 2017 09:12
LONDON--5 Oct--PRNewswire/InfoQuest

Pilatus Clinical Services are delighted to announce another addition to our management team. Mr Ian Hoban, previously Commercial Manager at Eli Lilly, will now fulfil the role of Sales & Marketing Director. Ian has close to 30 years of experience in the pharmaceutical industry, acting in a variety of roles including those of senior leadership at both Pfizer and Eli Lilly.

http://mma.prnewswire.com/media/565190/Ian_Hoban.jpg

In his most recent position, Ian was responsible for managing the commercial development of numerous therapeutic brands, from development through to product launch and ultimately to loss-of-exclusivity. Ian is well-versed in the pharmaceutical supply chain and understands how getting the optimal solution in place is fundamental to the delivery of successful project outcomes.

Ian is no stranger to the clinical trials supply arena. Before his function as a Business Development Director, he held a consultative role at a major pharmaceutical company; helping deliver added value to their customers and partners following the acquisition of a number of diversified businesses.

'Our commercial footprint is growing. With the incorporation of our sister company; PCS GmbH in Germany and future expansions in the pipeline, we are confident in achieving our goal of providing smarter comparator sourcing solutions to the clinical trial community. Myself, and the remaining board members are excited at the prospect of working with Ian to capitalise on these expansions and maximising Pilatus' brand in the comparator sourcing space,' said Julian Wolfe, Commercial Director at Pilatus Clinical Services.

Ian has a passion for collaboration and has seen how business partnerships can deliver strategic insight. At Pfizer UK, in the Established Products Business Unit, Ian oversaw the implementation of numerous techniques and witnessed how they transformed business outcomes in a highly competitive space.

This is another great advancement for the Pilatus group, improving our status as a leading service provider in comparator sourcing for clinical trials.
durotimi@pilatuspharma.com
T: +44 (0) 1923 204310
Source: Pilatus Clinical Services Ltd.

Latest Press Release

ESMO Publishes New Position Paper on Supportive and Palliative Care

ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care [ https://doi.org/10.1093/annonc/mdx757 ], calling attention to the evolving and growing gap between the needs of cancer...

Koch Disruptive Technologies to Lead $150 Million Investment of INSIGHTEC

The medical device company is transforming neurological treatments through its non-invasive focused ultrasound applications Koch Disruptive Technologies, a subsidiary of Koch Industries focused on finding and funding innovative and emerging companies,...

MediaTek Sensio: New Biosensor Solution Brings Health Monitoring to Smartphones

MediaTek Inc. today unveiled MediaTek Sensio(TM), the first 6-in-1 smartphone biosensor module. MediaTek Sensio is a powerful advanced health monitoring solution which makes it easy to track heart rate information, blood pressure trends, peripheral...

Merck Signs Distribution Agreement with Avanti(R) Polar Lipids

Merck , a leading science and technology company, today announced that it has entered into an agreement with Avanti(R) Polar Lipids to be the exclusive multinational distributor of the USA-based company's research lipids portfolio outside of the United...

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study looked at people with type 2...

Related Topics